M. R. Grever

771 total citations
20 papers, 343 citations indexed

About

M. R. Grever is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, M. R. Grever has authored 20 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in M. R. Grever's work include Chronic Lymphocytic Leukemia Research (11 papers), Advanced Breast Cancer Therapies (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). M. R. Grever is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Advanced Breast Cancer Therapies (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). M. R. Grever collaborates with scholars based in United States, Malaysia and Ukraine. M. R. Grever's co-authors include Louis Malspeis, Wayne D. Inman, Jaime Rodrı́guez, Gurmeet Kaur, P. Crews, Edward A. Sausville, Kimberly L.K. Duncan, Adrian M. Senderowicz, Michaele C. Christian and Bruce D. Cheson and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Infectious Diseases.

In The Last Decade

M. R. Grever

20 papers receiving 330 citations

Peers

Countries citing papers authored by M. R. Grever

Since Specialization

Citations

This map shows the geographic impact of M. R. Grever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. R. Grever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. R. Grever more than expected).

Fields of papers citing papers by M. R. Grever

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. R. Grever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. R. Grever. The network helps show where M. R. Grever may publish in the future.

Co-authorship network of co-authors of M. R. Grever

This figure shows the co-authorship network connecting the top 25 collaborators of M. R. Grever. A scholar is included among the top collaborators of M. R. Grever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. R. Grever. M. R. Grever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS 2015 ·Haematologica ·Jasmin Bahlo, Nadine Kutsch, Michael Bergmann, (unknown), Hartmut Doehner, Barbara Eichhorst, Monica Else, Christian H. Geisler, M. R. Grever, Stéphane Leprêtre, Donna Neuberg, D. Oscier, Tadeusz Robak, (unknown), Tait D. Shanafelt, Stephan Stilgenbauer, Michael Hallek	6
2	Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. 2011 ·Journal of Clinical Oncology ·Joseph M. Flynn, Justin A. Jones, Leslie A. Andritsos, Kristie A. Blum, (unknown), (unknown), Elizabeth Wiley, NA Heerema, Jennifer Poon, Karen Small, Ying-Ming Jou, (unknown), Paul Statkevich, M. R. Grever, Rajat Bannerji, John C. Byrd	10
3	A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). 2011 ·Journal of Clinical Oncology ·Sowmya Viswanathan, Robert Wesolowski, Rachel M. Layman, (unknown), Brandon Miller, (unknown), (unknown), Weiqiang Zhao, (unknown), (unknown), Mitch A. Phelps, Larry J. Schaaf, Susan M. Geyer, Nathan C. Hall, Michael V. Knopp, CL Shapiro, Miguel A. Villalona‐Calero, (unknown), M. R. Grever, (unknown)	3
4	A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·Amir Mortazavi, (unknown), Yang Ling, (unknown), Mitch A. Phelps, Igor Espinoza‐Delgado, J. Paul Monk, (unknown), M. R. Grever, Tanios Bekaii‐Saab	1
5	Phase I/II trial of reovirus serotype 3–Dearing strain in patients with recurrent ovarian cancer. 2010 ·Journal of Clinical Oncology ·David E. Cohn, Gerard J. Nuovo, Matt Coffey, David M. O’Malley, Miguel A. Villalona‐Calero, M. R. Grever, (unknown), James A. Zwiebel, Mitch A. Phelps	7
6	A novel liposomal formulation of flavopiridol 2008 ·International Journal of Pharmaceutics ·Xiaoyan Yang, Xinfeng Zhao, Mitch A. Phelps, Longzhu Piao, Darlene M. Rozewski, Qian Liu, Linda Lee, Guido Marcucci, M. R. Grever, John C. Byrd	38
7	Phase I study of 5-aza-2’-deoxycytidine in combination with valproic acid in patients with NSCLC 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), Josephine Aimiuwu, (unknown), (unknown), Miguel A. Villalona‐Calero, (unknown), K.C. Allen Chan, M. R. Grever, (unknown)	5
8	Treatment of Relapsed Chronic Lymphocytic Leukemia: Old and New Therapies 2006 ·Seminars in Oncology ·(unknown), (unknown), M. R. Grever	24
9	Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy 2006 ·Journal of Clinical Oncology ·M. R. Grever, G Dewald, Donna Neuberg, John C. Reed, Shinichi Kitada, Ian W. Flinn, Frederick R. Appelbaum, Richard A. Larson, Martin S. Tallman, John G. Gribben, John C. Byrd	1
10	Chronic Lymphocytic Leukemia: Introduction 2006 ·Seminars in Oncology ·(unknown), M. R. Grever	1
11	Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL) 2006 ·Journal of Clinical Oncology ·T. S. Lin, Beth Fischer, Mollie E. Moran, (unknown), Eric H. Kraut, Pierluigi Porcu, Sherif S. Farag, (unknown), A. D. Colevas, M. R. Grever, John C. Byrd	3
12	Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC) 2004 ·Journal of Clinical Oncology ·Miguel A. Villalona‐Calero, Gregory A. Otterson, (unknown), Keigo Kobayashi, (unknown), Donn C. Young, Teng‐Kuang Yeh, Soo‐Chang Song, M. R. Grever, Jessie L.‐S. Au	1
13	Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN) 2004 ·Journal of Clinical Oncology ·Chris A. Rhoades, Eric H. Kraut, David Schuller, (unknown), Chun Chan, Kathleen Lang, Charis Eng, M. R. Grever	3
14	P-229 Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients 2003 ·Lung Cancer ·Miguel A. Villalona‐Calero, Gregory A. Otterson, (unknown), Anthony J. Murgo, (unknown), Teng‐Kuang Yeh, (unknown), Soo‐Chang Song, M. R. Grever, Jessie L.‐S. Au	5
15	Carboxyamido-Triazole (CAI)-a Novel “static” Signal Transduction Inhibitor Induces Apoptosis in Human B-Cell Chronic Lymphocytic Leukemia Cells 2001 ·Leukemia & lymphoma ·Jamie K. Waselenko, Charlotte Shinn, C. R. Willis, Ian W. Flinn, M. R. Grever, John C. Byrd	7
16	Herpes Zoster and Lymphopenia Associated with Sodium Stibogluconate Therapy for Cutaneous Leishmaniasis 1998 ·Clinical Infectious Diseases ·Glenn Wortmann, Naomi Aronson, John C. Byrd, M. R. Grever, Charles N. Oster	22
17	Jasplakinolide's Inhibition of the Growth of Prostate Carcinoma Cells In Vitro With Disruption of the Actin Cytoskeleton 1995 ·JNCI Journal of the National Cancer Institute ·Adrian M. Senderowicz, Gurmeet Kaur, (unknown), (unknown), Wayne D. Inman, Jaime Rodrı́guez, P. Crews, Louis Malspeis, M. R. Grever, Edward A. Sausville, Kimberly L.K. Duncan	131
18	New chemotherapeutic agents in non-small-cell lung cancer. 1993 ·PubMed ·(unknown), Michaele C. Christian, Bruce D. Cheson, M. R. Grever, (unknown)	35
19	A comprehensive phase I and II clinical investigation of fludarabine phosphate. 1990 ·PubMed ·M. R. Grever, (unknown), (unknown), (unknown), (unknown), S P Balcerzak, (unknown)	22
20	Phase I Clinical Investigation of Fludarabine Phosphate by a Loading-Dose and Continuous-Infusion Schedule 1988 ·JNCI Journal of the National Cancer Institute ·(unknown), M. R. Grever, Alfred E. Staubus, James A. Neidhart, Louis Malspeis	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact